ASSEMBLY BIOSCIENCES,INC. (NASDAQ:ASMB) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02 Departure of Directors or Certain Officers; Election of Directors; Compensatory Arrangements of Certain Officers.
Effective as of April 2, 2018, Thomas E. Rollins, Chief Development Officer of Assembly Biosciences, Inc. (the “Company”) and a named executive officer of the Company, transitioned his duties as an executive officer, including his policy-making functions, to the Company’s newly hired Senior Vice President, Chief Scientific Officer Microbiome, Jacqueline S. Papkoff, Ph.D. Mr. Rollins will remain with the Company, and this change in his responsibilities will allow him to focus on alliance management and development.
About ASSEMBLY BIOSCIENCES,INC. (NASDAQ:ASMB)
Assembly Biosciences, Inc. is a biotechnology company. The Company is engaged in developing approximately two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral biological therapeutics, which are designed to restore health to a dysbiotic microbiome. It has discovered various core protein Allosteric Modulators (CpAMs), which are small molecules that directly target and allosterically modulate a number of Hemoglobin C functions. The Microbiome Program consists of an integrated platform that includes a strain identification and selection process, methods for strain isolation and growth under current good manufacturing practice (cGMP) conditions, and a delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. The lead program from this platform, AB-M101, is in development for the treatment of C. difficile-infections.